Summary of the Conference Call for Dao's Technology Company and Industry Overview - **Company**: Dao's Technology - **Industry**: Semiconductor and High-Performance Computing (HPC) Key Points and Arguments 1. Dao's Technology has entered the chip research, production, and sales sector through its 80% stake in the computing power center, aiming to expand market influence and support R&D for research institutions and enterprises, marking a significant step in industrialization [2][3] 2. The company focuses on the design of APU (Atomic Processing Unit) chips using a fabless model, outsourcing production to foundries like TSMC and SMIC. The APU is primarily used for atomic-level scientific computing, with a projected market size in China reaching hundreds of billions of RMB annually, and currently no direct competitors [2][6] 3. The APU chip features a storage-computing integrated brain-like architecture, significantly improving computation speed and reducing energy consumption by two to three orders of magnitude compared to traditional GPUs and CPUs, particularly excelling in atomic-level scientific calculations [2][9] 4. The He Xi Atomic Computing Center, co-established by Dao's Technology, plans to invest approximately 200 He Xi architecture servers, with completion expected in 2025 and further expansion in 2026 [2][10] 5. The supercomputing service market is valued at hundreds of billions of RMB, with atomic-level scientific computing accounting for 50%-75% of this market, indicating a potentially underestimated market space [2][11] 6. The APU chip has significant growth potential, akin to the transformative impact of GPUs on AI, with the ability to unlock a trillion-level market in material research [2][12] Additional Important Insights 1. Dao's Technology has established a partnership with Professor Liu Jie’s team to develop the Guangdong Xin Pei Sen platform, where Dao's holds a 20% stake, focusing on chip R&D, production, and sales [3] 2. The APU chip has already been applied in fields such as new energy material design, outperforming Nvidia's banned GPU by an order of magnitude and being three times faster than imported CPUs [4][14] 3. The company’s business model includes time leasing, hardware sales, and technical services, with a focus on providing tailored solutions based on customer needs [4][16] 4. The APU chip is positioned as a high-precision, high-performance solution for atomic-level scientific calculations, providing distinct advantages over general-purpose GPUs [7][43] 5. The company has received positive feedback from major clients in the materials sector, including Ningde Times and Zhuhai Guangyu, confirming the performance advantages of their computing services [31] 6. Dao's Technology emphasizes its core barriers, including the integration of complex atomic-level scientific computing algorithms into the APU chip and the proprietary software ecosystem that supports its hardware [32] Market and Competitive Landscape 1. The APU chip's market is currently dominated by Dao's Technology, with no direct competitors in the atomic-level scientific computing niche [6][13] 2. The company plans to maintain its focus on scientific computing rather than entering the general computing market, which is already saturated with established solutions [47] 3. The company is also exploring the integration of large model technologies to meet domestic computing demands [45] Future Developments 1. Dao's Technology is in the process of developing ASIC chips, with the first MPW tape-out completed in 2023 and plans for further product iterations in 2026 [48][49] 2. The company aims to expand its computing power center and establish additional training centers in collaboration with local governments and partners [10][52]

Core Viewpoint - JingTai Holdings (02228) has experienced a significant stock increase of over 10% following the announcement of a positive earnings forecast, indicating a strong financial outlook driven by strategic partnerships in AI-driven drug discovery [1] Financial Performance - The company anticipates a consolidated revenue of no less than RMB 500 million for the mid-2025 period, representing an increase of at least approximately 387% year-on-year [1] - Projected net profit is expected to be no less than RMB 50 million, with adjusted net profit anticipated to reach at least RMB 120 million [1] - This marks the company's first instance of achieving half-year profitability [1] Strategic Partnerships - The financial improvement is primarily attributed to a collaboration with DoveTree Medicines LLC and its affiliates, leveraging an end-to-end AI drug discovery platform and comprehensive "AI + Robotics" technology [1] - The partnership has resulted in a significant revenue boost, with an initial payment of USD 51 million recognized as revenue for the mid-2025 period, contributing substantially to the company's earnings during the reporting period [1] Market Position and Future Outlook - Dongwu Securities has highlighted the company as a rare player in the global AI for Science sector, considering the partnership a milestone event [1] - The initial payment amount exceeded expectations, validating the value of JingTai's AI and robotics technology in drug discovery [1] - The company's business model is beginning to take shape, laying a solid foundation for future commercial orders and rapid revenue growth in the medium to short term [1] - The client base for the company spans various sectors, including new materials, energy, and chemicals, further expanding the company's growth potential [1]

东吴证券近期指出，公司为全球AI for Science稀缺标的，此次合作对于公司是里程碑事件，首付款金额 高于预期，证明了晶泰控股的人工智能+机器人技术在药物发现领域的价值，同时其商业模式已初具雏 形，为未来商业化订单落地打下坚实基础，未来中短期收入有望迎来快速增长；同时公司合作客户涵盖 新材料、能源、化工等领域公司，进一步打开公司成长天花板，建议重点关注。 消息面上，晶泰控股近日发盈喜，预期截至2025年中期期间的集团综合收益将不少于人民币5亿元，同 比增加至少约387%；纯利不少于人民币5000万元；经调整纯利不少于人民币1.2亿元。这是集团首次实 现半年盈利。财务预期改善主要由于集团与DoveTree Medicines LLC及其联属公司合作，集团基于端到 端人工智能药物发现平台及综合"AI+机器人"技术，向DoveTree提供药物发现解决方案及服务，该合作 带动重大收益增长。集团收到首付款5100万美元，首付款已确认为集团于2025年中期期间的收益，并为 集团于报告期间的收益作出重大贡献。 智通财经APP获悉，晶泰控股(02228)涨超10%，截至发稿，涨10.34%，报8.22港元，成交额21. ...

Core Insights - The article discusses the challenges and opportunities in the AI investment landscape, particularly focusing on the contrasting positions of China and the US in AI financing and technology development [3][4]. Group 1: Global AI Landscape - Despite the near parity in generative AI applications between Chinese and American companies, China's share of global AI financing is shrinking, with top Chinese firms valued at only 2% of their US counterparts [3]. - The US export controls pose significant challenges for China's AI industry, particularly in terms of computational power [3]. Group 2: DeepSeek's Breakthrough - DeepSeek, an AI company incubated by a quantitative fund, has utilized a full-stack open-source strategy to achieve significant results, training with approximately $6 million and 2,000 H800 GPUs, costing only 6% of GPT-4's training expenses [4]. - Within 20 days of launch, DeepSeek surpassed 20 million daily active users, setting a new record for user acquisition in the internet sector [4]. Group 3: Ecosystem Reconstruction - The integration of DeepSeek's R1 inference engine with WeChat's 1.1 billion daily active users transforms user search behavior into "conversational demand expression," rendering traditional SEO ineffective [6]. - The introduction of GEO intelligent advertising services aims to help businesses seize the "answer discourse power" in the AI era [6]. Group 4: Investment Opportunities - A systematic analysis of over 300 AI companies has identified promising investment tracks for 2025, including Agentic AI, embodied intelligence and humanoid robots, small AI hardware revolution, and AI for Science [8]. Group 5: Future Directions - Generative AI currently accounts for less than 20% of the global AI market, indicating a need for deeper collaboration between production and research over the next decade [11]. - The company aims to serve as a strategic partner for enterprise AI upgrades, providing comprehensive services from trend forecasting to risk assessment [10][12].

Core Viewpoint - The strategic partnership between Biocytogen and Megvii Technology aims to enhance the digital and intelligent upgrade of fully human antibody research and production, leveraging their respective strengths in technology and automation to drive high-quality development in the biopharmaceutical industry [1][4][5]. Company Overview - Biocytogen is an international biotechnology company focused on innovative technology-driven drug development, with a comprehensive R&D platform covering target discovery, fully human antibody sequence development, preclinical evaluation, and collaborative transformation [3][10]. - The company has established a large-scale development system for antibodies through its "Thousand Mice, Ten Thousand Antibodies" program, which encompasses over a thousand potential drug targets and a library of over one million fully human antibody sequences [3][10]. - Megvii Technology is a leading provider of autonomous agents in the field of robotics, dedicated to offering comprehensive solutions for smart laboratories and intelligent manufacturing scenarios [10][11]. Strategic Cooperation Details - The collaboration focuses on integrating Biocytogen's technical expertise in antibody development with Megvii's innovative automation capabilities to create an intelligent upgrade system for antibody discovery, preparation, and screening [4][5]. - The partnership aims to optimize research labor input through a multi-agent solution, achieving automation at a scale exceeding one million, thereby enhancing the efficiency and precision of antibody preparation [4][5]. - The LabillionTM data intelligence system will facilitate the efficient integration, real-time analysis, and deep correlation of sequence and functional data generated from high-throughput screening [4][5]. Future Implications - The collaboration is expected to accelerate the innovation process of antibody drugs and explore new models driven by AI and automation, contributing to higher quality development in the biopharmaceutical industry [5][7]. - The integration of Megvii's autonomous intelligent agents with Biocytogen's advanced platforms is anticipated to address core challenges in large-scale antibody discovery and screening, setting a benchmark for the application of AI in the biopharmaceutical sector [7][9].

Group 1 - AI for Science (AI4S) has become a new paradigm in scientific research, entering an accelerated development phase, utilizing deep learning to solve core challenges in life sciences, materials science, and chemical reactions [7][8][21] - The development of AI4S has led to new collaborative states, with companies either using AI algorithms for contract research or building internal AI platforms for innovation [14][16] - Domestic AI development is increasingly focused on AI+ applications, with large enterprises beginning to consider early-stage layouts [21][25] Group 2 - AI4S applications are addressing three major industry pain points, including efficient information extraction, primary artificial replacement, and deep model predictions for initial assessments [32][33] - Innovation is the main theme of AI applications in the chemical industry, with a focus on six sub-sectors, including strain selection and process optimization in the fermentation industry [37][38] - AI4S applications are characterized by long R&D cycles and high costs, data-driven approaches, and high-dimensional design spaces, which traditional experiments cannot validate individually [36][33] Group 3 - The investment landscape includes companies like JingTai Technology, ZhongKong Technology, and ZhiTe New Materials, which are positioned to benefit from AI4S advancements [4][18] - The AI industry chain has seen significant growth, with upstream and midstream sectors developing rapidly under strong policy support, leading to increased capacity and innovation in hardware and software [25][26][27] - The government is actively promoting AI research cooperation, with initiatives aimed at integrating AI into solving major issues like climate and health [18][20]

Core Viewpoint - Insulation materials play a crucial role in achieving energy efficiency and reducing carbon emissions, aligning with the "dual carbon" goals of the country [2][11]. Group 1: Types of Insulation Materials - Insulation materials can be categorized into four main types: organic insulation materials, inorganic insulation materials, new materials, and composite materials [18][25]. - Organic insulation materials are characterized by their porous structure and low density, making them widely applicable in construction and industrial fields [18][22]. - Inorganic insulation materials feature high porosity and nano-scale pore structures, effectively reducing heat conduction [22]. - New materials focus on optimizing performance through thermal conduction path regulation, radiation suppression, and structural stability [25]. - Composite materials combine two or more materials to enhance overall performance [26]. Group 2: Market Opportunities - The market for insulation materials is projected to exceed hundreds of billions, with new insulation materials rapidly penetrating various sectors [4][32]. - In the power battery sector, the demand for thermal management and flame-retardant insulation materials is expected to surpass 90 million square meters by 2025, corresponding to a market size of approximately 6.3 billion yuan [4][49]. - The building energy-saving market is anticipated to reach 248.5 billion yuan by 2025, with a year-on-year growth of 13.8% [63]. - The oil and gas pipeline insulation materials market is projected to reach 10.96 billion yuan by 2025 [4]. Group 3: Innovations in Insulation Materials - The emergence of super insulation materials, such as aerogels, presents significant industrialization prospects [5]. - Super insulation materials have a thermal conductivity coefficient lower than that of "still air," with room temperature thermal conductivity typically below 0.04 W·m⁻¹·K⁻¹ [5]. - Companies like Zhite New Materials are leveraging AI for material research and development, significantly enhancing performance while reducing costs [5]. Group 4: Specific Applications - In the power battery sector, the use of aerogel insulation materials is expected to grow due to the increasing sales of new energy vehicles and the rising proportion of high-nickel batteries [4][50]. - In the construction sector, insulation materials are crucial for reducing heat loss, with external wall insulation being a primary focus [55][58]. - The oil and gas industry utilizes insulation materials to effectively protect against heat loss during transportation [4][32].

Macro Strategy - The report analyzes three historical cases of capacity adjustment over a century, providing insights into supply-demand rebalancing: the long depression in the late 19th century in Europe and America, the 1929 Great Depression, and Japan's capacity reduction in the 1970s and 1990s [1][11] - Key conclusions include that capacity imbalance can lead to a negative feedback loop lasting 20-30 years if uncontrolled, and government intervention is more effective than non-intervention in addressing capacity imbalances [1][11] - Effective supply-demand rebalancing requires simultaneous efforts in controlling capacity, restoring credit, and stabilizing employment, rather than relying solely on supply or demand policies [1][11] Fixed Income - The report discusses the micro-guided convertible bond, which has a total issuance scale of 1.17 billion yuan, with net proceeds used for the construction of an intelligent factory for semiconductor thin film deposition equipment [2][12] - The expected listing price range for the convertible bond is between 128.84 and 143.03 yuan, with a predicted subscription rate of 0.0036% [2][12] - The company, Micro-Guided Nano, has shown steady revenue growth with a compound annual growth rate of 71.44% from 2020 to 2024, achieving 2.7 billion yuan in revenue in 2024, a year-on-year increase of 60.74% [2][12] Industry Analysis - The report on Chuanfeng Power highlights the company's leading position in the all-terrain vehicle and motorcycle markets, with three major business segments experiencing rapid growth [3][14] - The investment recommendation maintains a "buy" rating for Chuanfeng Power, anticipating higher valuations due to its significant market position and growth potential across its business segments [3][14] - Jiuhua Tourism is positioned to leverage its unique cultural and natural resources, with projected net profits of 220 million, 240 million, and 270 million yuan from 2025 to 2027, corresponding to price-earnings ratios of 18, 16, and 15 times [4][14] Company-Specific Insights - Crystal Technology has secured a significant contract for drug discovery, with potential payments exceeding 5.89 billion USD, indicating strong future growth prospects [5][16] - The company is expected to achieve revenues of 552 million, 924 million, and 1.503 billion yuan from 2025 to 2027, with a forecasted return to profitability by 2027 [5][16] - Zhongchong Co., a leader in the pet food industry, reported a 42.6% year-on-year increase in net profit for the first half of 2025, driven by strong growth in its proprietary brands [17][18]

Group 1 - The core event involves JingTai Holdings utilizing its AI and robotics platform for drug discovery, leading to a significant financial agreement with DoveTree, including initial payments of $51 million and $49 million, and potential milestone payments totaling $5.89 billion [1] - DoveTree LLC, founded by Harvard professor Gregory Verdine, has a strong backing and a proven track record in biotechnology, which enhances the credibility and growth potential of the collaboration [2] - The partnership marks a milestone for JingTai Holdings, indicating the value of its AI and robotics technology in drug discovery, and sets a solid foundation for future commercialization and revenue growth [3] Group 2 - The financial projections for JingTai Holdings have been revised upwards due to the unexpected scale of the collaboration, with anticipated revenues of 552 million, 924 million, and 1.503 billion yuan from 2025 to 2027 [3] - The company is positioned as a rare player in the AI for Science sector, with the potential to achieve profitability by 2027, maintaining a "buy" rating [3]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has secured significant orders, indicating the initial formation of its business model, which is set to disrupt traditional paradigms in drug discovery [7] - The collaboration with DoveTree LLC, which includes substantial upfront payments and potential milestone payments, highlights the value of the company's AI and robotics technology in drug discovery [7] - The endorsement from a renowned Harvard professor suggests promising future growth for the company [7] - The company is identified as a rare player in the AI for Science sector, with its business model beginning to take shape, paving the way for future commercial orders and rapid revenue growth [7] - The financial forecasts have been revised upwards due to the unexpected scale of the collaboration, with projected revenues for 2025-2027 being 5.52 billion, 9.24 billion, and 15.03 billion respectively [7] Financial Projections - Total revenue is expected to grow from 266.43 million in 2024 to 1,502.54 million by 2027, reflecting a compound annual growth rate of 62.62% [1] - The company is projected to achieve a net profit of 62.87 million by 2027, after losses in the preceding years [1] - The earnings per share (EPS) is expected to improve from -0.38 in 2024 to 0.02 in 2027 [1] - The price-to-earnings (P/E) ratio is projected to shift from -17.48 in 2024 to 421.67 in 2027, indicating a significant change in valuation as the company approaches profitability [1]